Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

RGC stock hub

Regencell Bioscience Holdings Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RGCis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

14.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RGC

In the news

Latest news · RGC

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-177.7

P25 -105.6P50 -46.5P75 -3.1

ROIC-107.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RGC market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

165

Groups with data

Currency

USD

Showing 165 of 165 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001829667
Company name	Regencell Bioscience Holdings Limited
Country	Hong Kong
Country code	US
Cusip	G7487R100
Employees	10
Employees Change	-2%
Employees Change Percent	-16.67
Enterprise value	$14.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2021-07-16
Isin	KYG7487R1002
Last refreshed	2026-05-10
Market cap	$14.5B
Market cap category	Large-Cap
Price	$29.28
Price currency	USD
Sector	Healthcare
Sic	2833
Symbol	RGC
Website	https://www.regencellbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.05%
FCF yield	-0.02%
P/B ratio	11,873.74x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-7M
Net Income Growth Years	3%
Profit Per Employee	$-704,859
ROA	-84.97
Roa5y	-68.19
ROCE	-529.3
ROE	-177.7
ROIC	-107.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	486.34%
Cagr3y	250.35%
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$3M
Cash	$2.4M
Current Assets	$4.9M
Current Liabilities	$663,673
Debt	$386,302
Debt Equity	$0.32
Equity	$1.2M
Liabilities	$1.8M
Long Term Assets	$-1.9M
Long Term Liabilities	$1.1M
Net Cash	$2M
Net Cash By Market Cap	$0.01
Net Cash Growth	-60.79%
Net Debt Equity	$-1.62
Tangible Book Value	$1.2M
Tangible Book Value Per Share	$0
WACC	14.51

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.42
Net Working Capital	$-1.4M
Quick ratio	1.42
Working Capital	$691,391

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	485.63%
200-day SMA	21.13
3Y total return	4,204.22%
50-day SMA	27.23
50-day SMA vs 200-day SMA	50over200
All Time High	83.6
All Time High Change	-64.98%
All Time High Date	2025-06-16
All Time Low	0.08
All Time Low Change	36,637.77%
All Time Low Date	2024-07-22
ATR	2.56
Beta	1.86
Beta1y	0.25
Beta2y	-2.14
Ch YTD	39.43
High	31.9
High52	83.6
High52 Date	2025-06-16
High52ch	-64.98%
Low	28.32
Low52	5.3
Low52 Date	2025-05-08
Low52ch	452.98%
Ma50ch	7.55%
Premarket Change Percent	-0.54
Premarket Price	$31.3
Premarket Volume	1,262
Price vs 200-day SMA	38.6%
RSI	52.26
RSI Monthly	74.68
RSI Weekly	56.4
Sharpe ratio	1.47x
Sortino ratio	4.85
Tr YTD	39.43
Tr1m	5.1%
Tr1w	0.55%
Tr3m	7.53%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-7.1M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55,407,228%
Float Percent	11.2%
Shares Insiders	88.8%
Shares Institutions	0.18%
Shares Out	494,488,908
Shares Qo Q	0%
Short Float	1.5%
Short Ratio	4.49
Short Shares	0.17

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-3.5M
Average Volume	107,238.4x
Bv Per Share	0
CAPEX	$-152,689
Ch1m	5.1
Ch1w	0.55
Ch1y	485.6
Ch3m	7.53
Ch3y	4,204
Ch6m	124.9
Change	-6.96%
Change From Open	-5.73
Close	31.47
Days Gap	-1.3
Depreciation Amortization	77,692
Dollar Volume	2,812,139
Earnings Date	2026-06-29
Earnings Time	bmo
EBIT	$-7.1M
EBITDA	$-7.2M
EPS	$-0.01
F Score	1
FCF	$-3.3M
FCF EV Yield	-0.02x
FCF Per Share	$-0.01
Fiscal Year End	June
Founded	2,014
Investing CF	4,934,699
Ipr	208.2
Iprfo	9,171.7
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2025-10-31
Last Report Date	2025-06-30
Last Split Date	2025-06-16
Last Split Type	Forward
Last10k Filing Date	2025-10-31
Ma150	23.5
Ma150ch	24.59%
Ma20	29.08
Ma20ch	0.71%
Net CF	780,974
Next Earnings Date	2026-06-29
Open	31.06
Optionable	Yes
Position In Range	26.82
Post Close	29.28
Postmarket Change Percent	0.75
Postmarket Price	$29.5
Ppne	759,819
Pre Close	31.47
Price Date	2026-05-08
Ptbv Ratio	11,873.7
Relative Volume	0.9x
Share Based Comp	244,808
Tr6m	124.89%
Volume	96,043

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RGC pay a dividend?

Capital-return profile for this ticker.

Performance

RGC stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RGC?

Insider, institutional, and short-interest positioning.

Institutional ownership

+0.2%

Float: +11.2% of shares outstanding

Insider ownership

+88.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RGC momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.3

Neutral momentum band

Price vs 200-day MA

+38.6%

50/200-day relationship not available

Beta (5Y)

1.86

More volatile than the market

Sharpe ratio

1.47

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RGC

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RGC stock rating?

Regencell Bioscience Holdings Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RGC analysis?

The full report lives at /stocks/RGC/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RGC?

The latest report frames RGC around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RGC page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.